We Aim to Bring Much-Needed Medicines to Patients
We currently developing tamibarotene, an investigational medicine for patients with MDS and AML.
Tamibarotene for RARA Overexpression in MDS and AML
Tamibarotene (formerly SY-1425) is an oral, selective retinoid acid receptor alpha (RARĪ±) agonist that we are developing in newly diagnosed patients with RARA gene overexpression with higher-risk myelodysplastic syndrome (HR-MDS) and newly diagnosed acute myeloid leukemia (AML) patients with RARA gene overexpression who are not suitable candidates for standard intensive chemotherapy.
High response rates, rapid onset of responses and clinically meaningful durability were shown in a Phase 2 study of tamibarotene in combination with azacitidine in newly diagnosed AML patients with RARA overexpression who are not suitable candidates for standard chemotherapy, including in patients with low blast count AML. Data also showed that tamibarotene in combination with azacitidine was generally well tolerated, with no increase in toxicities beyond what has been previously seen with either agent alone. Additionally, data from a translational analysis of these trial patients also suggest that patients with RARA overexpression may be less likely to respond to the current standard of care.
These data support the advancement of tamibarotene into two ongoing clinical trials: first, our Phase 3 SELECT-MDS-1 trial of tamibarotene in combination with azacitidine in newly diagnosed higher-risk MDS patients with RARA overexpression, a hematologic malignancy that is closely related to AML; and second, our randomized Phase 2 SELECT-AML-1 trial in combination with venetoclax and azacitidine in newly diagnosed unfit AML patients with RARA overexpression.
 Downloadable MDS Trial Fact Sheet |
 Downloadable AML Trial Fact Sheet |
Read more about our Phase 3 trial in HR-MDS Read more about our Phase 2 trial in AML
Interested in Learning More about How Clinical Trials Work?
Clinical trials are an important part of helping bring safe and effective medicines to patients. For patients who lack effective treatments, clinical trials are also an opportunity to be a part of testing a new drug. By taking part in clinical trials, patients can make an important contribution to ongoing research and better understanding of a disease.
Learn more about participating in clinical trials
Access to Investigational Products Outside of a Clinical Trial
Syros has adopted a policy that describes the guidelines by which it will consider requests for access to one of its investigational products outside of a clinical trial.